Boosting HIV Treatment Options: Good News, New Challenges

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro

(2012) Eve-Irene Lepist et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

(2012) Polina German et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Treatment of Adult HIV Infection

(2012) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

(2011) Richard Elion et al.   AIDS

Biological Profiling of GS-9350, a Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In Vitro

(2010) Christian Callebaut et al.   ANTIVIRAL RESEARCH

Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients

(2010) Ryan D. Cooper et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

(2009) A A Mathias et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy

(2007) Miguel Goicoechea et al.   JOURNAL OF INFECTIOUS DISEASES